Kornimate/medical-research-clean huggingface dataset:
rri compared with nephrochecktm to predict acute renal failure after cardiac surgery.

Conditions: Cardiac Surgery; Extracorporeal Circulation; Nephrocheck; Renal Failure

Summary: postoperative acute renal failure is a frequent complication after cardiac surgery. the current practice cannot predict acute kidney injuries (aki) early enough to reduce a significant kidney assault and prevent an organic dysfunction leading to cortical tubular necrosis. several recent studies in cardiac surgery have shown that, both sonographic criteria, such as the renal resistive index (irr) and urinary biomarkers can predict aki promptly. these urinary biomarkers are the 'tissue inhibitor of metalloproteinases' (timp-2) and the 'insulin-like growth factor binding protein' (igfbp7). these two proteins are sought noninvasively, directly in the urine, within the same test called 'nephrochecktm'. these markers, ultrasonographic and biologic, have the advantage of being easy to perform, accessible and seem to have both high sensitivity and specificity to predict aki promptly after cardiac surgery. thus, the irr and the nephrochecktm test could become essential tests to guide clinicians in determining rapidly whether a patient will develop aki. however, so far, no study has compared these markers yet. therefore, the aim of this prospective observational study will be to compare the effectiveness of the irr with the nephrochecktm to predict aki promptly after cardiac surgery. the secondary outcome will be to determine the threshold of these markers from which patients will be likely to develop aki


Eligibility criteria:
inclusion criteria: * elective patients * patients scheduled to receive an extracorporeal circulation * patients aged 60 and older * patients at risk of postoperative acute kidney injury presenting at least two of the following risk factors: * age \> 60 years. * arteritis defined as severe lower limb arteriopathy or carotid stenosis \> 50% * diabetes * valvular or combined surgery * preoperative intra-aortic balloon pump. exclusion criteria: * unable to provide informed consent * comatose patients * patients with dementia * patient who underwent a previous sternotomy * chronic renal failure (scr clearance \< 30 ml.min-1) * renal artery stenosis * endocarditis * emergent surgery * nephrotoxic treatment * non-sinus cardiac rhythm

Keywords: cardiac surgery extracorporeal circulation renal failure
atorvastatin pre-treatment influences the risk of percutaneous coronary intervention study

Conditions: Coronary Artery Disease

Summary: this study investigates potential protective effect of atorvastatin pre-treatment in patient with stable coronary artery disease undergoing percutaneous coronary intervention (pci). patient are randomized to two groups: atorvastatin pre-treatment group (80mg atorvastatin two days before pci) and control group (pci without atorvastatin pretreatment). endpoint is myocardial infarction measured by troponin i and creatine kinase myocardial band.

randomized studies have shown that pre-treatment with atorvastatin may reduced periprocedural myocardial in patient with stable angina during elective pci. these data provide evidence-based support for using atorvastatin 7 days before pci (dosage 40mg/d), alternatively three or more days (unknown dosage). we want to confirm this results for shorter pre-treatment period (two days) with dosage 80mg per day.

Eligibility criteria:
inclusion criteria: * stable angina in last month * indication for percutaneous coronary intervention * informed consent exclusion criteria: * acute coronary syndrome in last 14 days * renal insufficiency (creatinine more 150 µmol/l) * diseases severely limiting prognosis * immunosuppressive treatment * statin one month before randomization * occlusion of the coronary artery * previous participation in this study

Keywords: coronary artery disease percutaneous coronary intervention atorvastatin
non-colorectal liver metastases undergoing liver resection

Conditions: Liver Metastases

Summary: liver metastases (lm) are common in various types of malignant diseases, either at the diagnosis of the primary tumour or at a later time point. while the resection of colorectal lm (crlm) is a well-established procedure, with survival rates superior to chemotherapy alone, controversial data still exist on liver resection for non-colorectal lm (ncrlm) (2, 3). these patients comprise a diverse and heterogeneous group usually excluded from surgery due to advanced tumour stage or the presence of concomitant extrahepatic disease. to date, no randomized clinical trial on the surgical treatment of ncrlm has been conducted, and only few retrospective reports are available.the scope of this research project is to develop a large registry of patients undergoing liver surgery for non-colorectal liver metastases.


Eligibility criteria:
inclusion criteria: * signature informed consent * age ≥ 18 years * histologically confirmed diagnosis of ncrlm (first diagnosis or relapse) * liver resection performed. exclusion criteria * asa iv * severe psychiatric pathology * unable to follow a clinical examination pattern during observation. * patient submitted exclusively to interventional locoregional procedures other than liver resection.
comparison of g-csf & antibiotics versus antibiotics alone in resolution of febrile neutropenia

Conditions: Febrile Neutropenia; Febrile Neutropenia, Rule of Clinical Decision, Chemotherapy; Febrile Neutropenia, Drug-Induced; G-CSF; Antibiotic Therapy

Summary: this study aim to find the best option for children having cancer who develop low immunity state due to chemotherapy

children having a cancer diagnosis and treated with chemotherapy often develop neutropenia. this creates an immunocompromised state which can result in infections manifested by fever. this study compares two treatment options to find out the best treatment for these patients.

Eligibility criteria:
inclusion criteria: * age 1-16 years * any gender * febrile neutropenia * diagnosed case of solid or hematological malignancy * taking chemotherapy exclusion criteria: * non-neutropenic fever * already received g-csf or antibiotics before presenting to hospital * any other cause of neutropenia

Keywords: febrile neutropenia chemotherapy-induced febrile neutropenia antibiotics g-csf
nabilone in cannabis users with ptsd

Conditions: Cannabis; Post Traumatic Stress Disorder

Summary: despite the prevalence of cannabis use among the ptsd population and self-reports that it is used to help cope with ptsd symptoms, the direct effects of cannabis on ptsd symptomology are unknown. the purpose of this placebo-controlled, within-subject study is to assess the effects of smoked cannabis and orally administered nabilone, a synthetic analog of thc, the primary psychoactive component of cannabis on multiple dimensions of ptsd symptomatology in cannabis smokers with ptsd.

this study will compare the effects of smoked cannabis and nabilone on attentional bias toward trauma- related stimuli, subjective and emotional processing to a range of trauma-and non-trauma-related images and physiological reactivity to these stimuli in individuals with cud and ptsd. importantly, this study will also probe the abuse related potential of nabilone compared to smoked cannabis in this population, a critical aspect in determining the potential feasibility for its use clinically to treat cud in ptsd populations. the effects of nabilone will be compared to propranolol as a positive control.

Eligibility criteria:
inclusion criteria: * current cannabis use * ptsd symptoms * able to give informed consent and comply with study procedures * women who are normally cycling and practicing an effective form of birth control other than hormonal contraceptives exclusion criteria: * meeting criteria for certain current psychiatric disorders * clinical laboratory tests outside of normal limits * history of clinically significant cardiac or respiratory diagnoses * current parole or probation * women who are currently pregnant or breastfeeding
effect of pbm on functional capacity and fatigability in post covid-19 elderly

Conditions: Post Covid-19 Elderly

Summary: participants had randomly divided into two equal groups. group (a) which is the study group will receive photobiomodulation session two times per week for four weeks. group (b) will be the control group that will receive placebo photobiomodulation two times per week for four weeks.

group (a): 1. each participant will sign a consent form after receiving a detailed explanation about the procedure. 2. submaximal exercise capacity using time up and go test will be assessed. 3. fatigability will be assessed using fatigue assessment scale. 4. hemodynamic variables including; blood pressure, heart rate, oxygen saturation, maximum oxygen consumption will also be assessed. 5. after one month all the assessment procedure will be repeated again. r group (b): 1. each participant will sign a consent form after receiving a detailed explanation about the procedure. 2. submaximal exercise capacity using time up and go test will be assessed. 3. fatigability will be assessed using fatigue assessment scale. 4. hemodynamic variables including; blood pressure, heart rate, oxygen saturation, maximum oxygen consumption will also be assessed. 5. after one month all the assessment procedure will be repeated again.

Eligibility criteria:
inclusion criteria: * 60 to 75 years of age * past history of covid 19 in the last year exclusion criteria: * ( history of a histologically demonstrated malignant carcinoma , hyperthyreosis , epilepsy, light sensitivity )
effects of perioperative operating room environment on postoperative delirium

Conditions: Postoperative Delirium

Summary: thi investigators aims to observe the impact of perioperative body temperature and the noise of operating room on postoperative delirium for elderly patients undergoing abdominal surgery. and based on this study the investigators aimed to explore the potential risk factors of postoperative delirium for elderly patients undergoing abdominal surgery.


Eligibility criteria:
inclusion criteria: * age 65-90 years old; * asa i-iii; * patients who plan to undergo elective abdominal surgery under general anesthesia; * volunteer to participate in this study and sign informed consent. exclusion criteria: * patients with known mental illness or lack of communication or cognitive impairment before operation; * severe vision, hearing, language impairment or other reasons unable to communicate with visitors; * severe dysfunction of important organs such as heart, brain, lung, liver, kidney, etc.; * long-term use of sedatives, antidepressants or alcoholism; * patients with severe postoperative complications and admitted to intensive care unit; * patients who refused or failed to complete the cognitive function test. * patients who could not cooperate with the study for any other reason.
evaluation of the microbiome in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: to access the small intestinal microbiome and find abnormal microbiome/metabolome signature in luminal fluid samples from small bowel in ms compared to hc that could be used as biomarkers for ms.

participants will be swallowing the simba capsule which allows for minimally-invasive sampling of the microbiome and metabolome deep in the small intestine. researchers will use the capsule samples to access the small intestinal microbiome and find abnormal metabolomic signatures in luminal fluid samples from the small bowel in multiple sclerosis (ms) patients compared to healthy control.

Eligibility criteria:
inclusion criteria: 1. age between 18 and 60 years inclusive. 2. have diagnosis of multiple sclerosis (relapsing remitting or secondary progressive for the ms cohort) or be a healthy individual living in the same household (non-ms for the healthy control cohort) 3. no antibiotics, or colon cleanses/bowel preparation in the previous 2 weeks. 4. written informed consent exclusion criteria: 1. known to have swallowing disorders 2. known disease which, in the investigator's opinion, would lead to intestinal stricture or obstruction with a risk of capsule non-excretion (particular diseases which would be assessed on a case-by-case basis would include, achalasia, eosinophilic esophagitis, diverticulitis, crohn's disease, ulcerative colitis, cancer diagnosis or treatment within the past year, or previous oesophageal, gastric, small intestinal, or colonic surgery. 3) appendectomy or cholecystectomy more than 3 months prior to enrolment are acceptable). the main deciding factor would be history of obstructive symptoms in the previous 3 months prior to entry. 3. use of any medications in the previous week that could substantially alter gastrointestinal motor function (e.g., opioids, prokinetics, anticholinergics, laxatives), or acidity (ppi, h2ra); for both groups. 4. \< 2 bowel movements per week (for both groups). 5. risk or suspect of being pregnant
electroacupuncture therapy for treating postherpetic neuralgia

Conditions: Postherpetic Neuralgia

Summary: postherpetic neuralgia (phn) has a high incidence rate and severely impact on quality of life and health care costs, interfering with physical, emotional and social functioning of affected patients. current therapeutic options for phn mainly include analgetic and local anaesthesia for selective nerve blockade. nevertheless, the efficacy of analgetic is always limited by inevitable side effects, in which patients have poor compliance. moreover, for some most suffering patients, the control of pain is often unsatisfactory despite the administration of complex combinations. as a non-pharmarceutical therapy, acupuncture is widely use for a wide range of pain conditions. thus, it might be an alternative treatment for phn. the aim of this multicenter randomized controlled trial is to investigate the efficacy and safety of electroacupuncture therapy in patients with postherpetic neuralgia.

this randomized controlled trial will enroll 132 patients with postherpetic neuralgia. all patients will be randomly assigned to either the ea combined with medication group or the medication group via a computerized central randomization system in a 1:1 ratio. primary outcomes will be change in sensory thresholds and pain intensity. secondary outcomes will be change in dosage of analgetic, quality of life, anxiety and depression severity and sleep quality.

Eligibility criteria:
inclusion criteria: 1. patients have a medical history of herpes zoster; 2. skin lesion has healed in the region of herpes zoster, but the duration of postherpetic neuralgia persist for more than 30 days. 3. 20 ≤ age ≤80 years, male or female 4. participants can fully understand the study protocol and written informed consent is signed. exclusion criteria: 1. acute herpes zoster, herpes zoster has not disappeared; 2. herpes zoster belongs to a special type, such as ophthalmic herpes zoster, auricular herpes zoster, hz that involves internal organs, meningeal herpes zoster, and disseminated herpes zoster. 3. pregnant or lactating women; 4. patients have severe complications in cardiovascular, cerebrovascular, liver, kidney, hematopoietic and other systems,or have malignant tumor, mental illness, immune deficiency, hemorrhagic disorders and other diseases; 5. patients have severe cognitive impairment and can not understand the study protocol; 6. patients can not receive electroacupuncture treatment due to any reasons.

Keywords: electroacupuncture postherpetic neuralgia pain randomized controlled trial protocol
a multi-institutional phase ii study of cyclophosphamide, paclitaxel, cisplatin with g-csf for patients with newly diagnosed advanced stage ovarian cancer

Conditions: Ovarian Neoplasm

Summary: a supra-additive cytotoxic effect was seen when cai and paclitaxel were given to human ovarian cancer cells sequentially in tissue culture. we have demonstrated that cai given for 8 days followed by paclitaxel is reasonably well tolerated and that paclitaxel administration causes a dose-dependent increase in cai plasma concentration. cai is a cytostatic drug and continuous exposure is needed. this study will evaluate the combination of continuously administered cai with three-weekly paclitaxel.

a supra-additive cytotoxic effect was seen when cai and paclitaxel were given to human ovarian cancer cells sequentially in tissue culture. we have demonstrated that cai given for 8 days followed by paclitaxel is reasonably well tolerated and that paclitaxel administration causes a dose-dependent increase in cai plasma concentration. cai is a cytostatic drug and continuous exposure is needed. this study will evaluate the combination of continuously administered cai with three-weekly paclitaxel.

Eligibility criteria:
* inclusion criteria: all patients must have biopsy proven, newly diagnosed epithelial ovarian cancer, primary epithelial fallopian tube cancer, or peritoneal surface carcinoma. histopathologic diagnosis must be confirmed in the pathology department of the treating institution prior to initiation of therapy. diagnosis will be confirmed in the laboratory of pathology, national cancer institute. this confirmation is not necessary prior to entering the patient onto protocol. patients must have figo stage iii or iv disease and will undergo attempted surgical debulking prior to the initiation of chemotherapy. patients must be able to begin therapy within 6 weeks of staging laparotomy and should have an indwelling venous access device placed. a double lumen catheter is preferred. performance status of less than or equal to ecog 2. patients must be able to give written informed consent and express a willingness to meet all of the expected requirements of the protocol. all patients must be registered by calling the orkand corporation at 301-402-1732 between the hours of 8:30 am and 5:00 pm est; eligibility criteria will be queried. exclusion criteria: evidence cns involvement (patients with normal clinical exam will not require a head ct scan or mri). history of myocardial infarction or unstable dysrhythmia within 1 month of study entry. creatinine clearance of less than 60 cc/min, anc less than 1000/cm3, platelet count less than 1000,000/cm3. history of active gi bleeding within the last 30 days. prior therapy other than surgery for this malignancy. abnormal pt, ptt, and bilirubin. sgot greater than or equal to 3 times the upper limit of normal. previous history of invasive malignancy. patients with ureteral obstruction must have this corrected prior to starting therapy. patients with germ cell, mixed muellerian and borderline histologies are specifically excluded.

Keywords: ovarian cancer initial therapy paclitaxel cisplatin cyclophosphamide
cycled light and crying of preterm infants

Conditions: Crying; Sleep

Summary: this study shows that cycled light during neonatal care reduces infant's fussing and crying behavior at 5 and 11 weeks corrected age and improves growth during neonatal care.


Eligibility criteria:
inclusion criteria: * very preterm infants (≤ 32 0/7 weeks gestational age, ga) exclusion criteria: * major cerebral injuries such as intraventricular haemorrhage grade iii (according to papile 16) or periventricular leukomalacia or venous infarction (according to govaert and de vries 17) diagnosed by cranial ultrasound * retinopathy of prematurity grade iii and iv * congenital malformations * small for gestational age (birth weight \< 3rd percentile) * prenatal infections * intrauterine drug exposure

Keywords: cycled light dim light circadian rhythm actigraphy, sleep premature infant
feasibility and efficacy of a digital training intervention to increase reward sensitivity- imager

Conditions: Stress

Summary: development and feasibility test of an ecological momentary intervention (emi) - imager, to promote and improve stress resilience, specifically to increase reward sensitivity.

aim of the current project is to develop and test ecological momentary intervention (emi) - imager, to promote and improve stress resilience, specifically to increase reward sensitivity. emis are mostly smartphone-based applications that deliver interventions to people as they go about in their daily lives. the emi developed and tested here is based on theoretical and empirical findings and consists of several items and a repeated training using various individual scenarios from participants' life that will be presented to participants via an app on their smartphones. this study tests the feasibility and effects of the emi on a change in (i) reward sensitivity, (ii) mental imagery, and (iii) indices of perceived stress. one hundred twenty healthy student participants, aged 18-29 will be included in the study. participants will be screened first and included if they score 5 points or more on the reward sensitivity subscale of behavioral avoidance/inhibition (bis/bas) scales. this is necessary in order to avoid a ceiling effect. then, participants will be randomly assigned to an experimental (reward sensitivity emi) or two of the control conditions (control ema or waitlist). the reward sensitivity emi group will be taught about experiencing rewards in daily life and will be asked to apply the specific techniques to personal situations repeatedly. the control ema group will use the same app consisting of ecological momentary assessment only, and the waitlist group will not receive any mobile app. the training will last seven consecutive days and the app will send (i) 10 prompts per day to ask about the current mood of the user in control ema and experimental groups and (ii) three prompts per day resulting in a total of 21 reward training sessions only in the experimental group. participants will be able to use a special button triggering the intervention or ema by themselves too. after one week, participants will return to the lab, fill in questionnaires and participate in behavioral tasks.

Eligibility criteria:
inclusion criteria: * being a student * having sufficient knowledge of the german language * being a smartphone user * score of 5 points or more in reward sensitivity subscale of behavioral avoidance/inhibition (bis/bas) scales exclusion criteria: * having a mental illness or attending the psychotherapy

Keywords: stress health resilience
extension study to assess the efficacy and safety of repeat treatment with rituximab (mabthera) in participants with active rheumatoid arthritis (ra)

Conditions: Rheumatoid Arthritis

Summary: this study will assess the long-term safety and efficacy of repeat treatment courses of rituximab, in combination with methotrexate in a disease-modifying anti-rheumatic drug (dmard) inadequate responder population of participants who were previously randomized into studies wa16291 (nct02693210) or wa17043/u2644g (nct00074438). the study permits multiple re-treatments until the protocol-defined end-of-treatment date (31 december 2011). participants will then enter a safety follow-up (sfu) period of at least 48 weeks. this will provide at least 7 years follow-up data on all participants initially randomized into wa16291 or wa17043/u2644g. approximately 600 participants will potentially be eligible to enter this open label extension study from their respective feeder studies.


Eligibility criteria:
inclusion criteria: * participants with active ra * completed 24 weeks of treatment in wa16291 or wa17043 * eligible for re-treatment, based on clinical symptoms (disease activity score in 28 joints \>=2.6) * females of childbearing potential using reliable contraception exclusion criteria: * participants who participated in rituximab studies wa16291 or wa17043 but withdrew into the safety follow-up phases of these trials * previous rituximab non-responders * current treatment with any other disease-modifying drug (apart from methotrexate), or any anti-tumor necrosis factor alfa, anti-interleukin-1, or other biologic therapies * participants with known active infection of any kind * evidence of any new or uncontrolled concomitant disease or development of any new contraindications which would preclude repeat treatment with rituximab * history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies * female participants who are pregnant or breastfeeding